DE

Dale Eadie

Clinical Research Program Manager at Adaptive Phage Therapeutics

Dale Eadie has extensive experience in the field of clinical research. They currently serve as a Clinical Research Program Manager at Adaptive Phage Therapeutics, where they oversee bacteriophage therapy trials and train site pharmacists in the administration of bacteriophage to study participants. Prior to this, Dale worked as a Contract Principal Clinical Research Associate at Planet Pharma, managing site operations for various immuno-oncology trials, including a CAR-T therapy trial for ALL. They also held the position of Senior Clinical Research Associate at Sarah Cannon Research Institute and PRA Health Sciences/Dedicated to Merck Oncology Studies, where they conducted research and monitoring for clinical trials. Earlier in their career, Dale worked at PSI CRO AG as a Sr. CRA, at Fresenius Medical Care as a Clinical Research Consultant, and at PharmaNet Development Group, Inc. as a Clinical Research Associate and Sr. Data Analyst. They also gained experience as a Clinical Data Analyst at Eximias Pharmaceuticals, a Data Validation Analyst at Quality Data Services, and a Clinical Data Coordinator at Omnicare Clinical Research.

Dale Eadie's education history includes a Bachelor of Science in Nursing (BSN) from Temple University. Additionally, they attended the Cittone Institute, although no specific degree or field of study was mentioned. Later on, Dale pursued a Master's in Healthcare Administration (MHA) at Saint Joseph's University.

In terms of certifications, Dale is a Certified Clinical Research Associate, obtained from the Association of Clinical Research Professionals (ACRP). They also hold a Registered Professional Nurse certification from the Commonwealth of Pennsylvania. However, specific dates for obtaining these certifications were not provided.

Location

Haddonfield, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Adaptive Phage Therapeutics

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.


Industries

Employees

11-50

Links